Federal Drug Scheduling & Controlled Substances Regulation

The Drug Enforcement Administration (DEA) administers the federal drug scheduling system under the Controlled Substances Act (CSA, 1970) (21 U.S.C. §§ 801–904), classifying substances into five schedules based on three factors: potential for abuse, whether there is a currently accepted medical use in treatment, and the potential for psychological or physical dependence. The scheduling of a substance determines its legal status, criminal penalties for trafficking and possession, prescribing requirements for physicians, and research barriers. Schedule I (heroin, LSD, MDMA, psilocybin, marijuana) represents the strictest classification — no accepted medical use and high abuse potential — making federally funded research extraordinarily difficult and creating the core federal-state conflict over marijuana, which 38+ states have legalized despite its Schedule I status. Schedule II (fentanyl, oxycodone, cocaine, methamphetamine, Adderall) has accepted medical uses but the highest abuse potential and strictest prescribing controls. The scheduling process — a joint scientific evaluation by HHS/FDA followed by a DEA rulemaking — is the mechanism through which the federal government's legal position on any given substance can change. The DEA's 2024 proposal to reschedule marijuana from Schedule I to Schedule III — following an HHS recommendation — represents the most significant potential scheduling change in decades, though the proposal faces public comment periods, administrative review, and legal challenge. International treaty obligations under the UN Single Convention on Narcotic Drugs (1961) also constrain what the U.S. can do with scheduling, as rescheduling marijuana may require treaty renegotiation.

Current Law (2026)

Legal Authority

• 21 U.S.C. § 811 — Authority and criteria for drug scheduling (Attorney General, through DEA, may add, remove, or transfer substances between schedules; must request scientific and medical evaluation from HHS/FDA; 8 statutory factors: actual/relative potential for abuse, scientific evidence of pharmacological effect, state of current scientific knowledge, history and current pattern of abuse, scope/duration/significance of abuse, risk to public health, psychic or physiological dependence liability, whether the substance is an immediate precursor of a controlled substance)
• 21 U.S.C. § 812 — Schedules of controlled substances (5 schedules with specific criteria; Schedule I: high abuse potential, no currently accepted medical use, lack of accepted safety; Schedule II: high abuse potential, currently accepted medical use, abuse may lead to severe psychological/physical dependence; continuing through Schedule V with decreasing abuse potential)
• 21 U.S.C. § 821-824 — Registration requirements (manufacturers, distributors, dispensers, and researchers must register with DEA; separate registrations for each schedule)
• 21 U.S.C. § 829 — Prescriptions (Schedule II: written prescription required, no refills; Schedule III-IV: oral or written prescription, up to 5 refills within 6 months; Schedule V: may be dispensed without prescription in some cases)
• 21 U.S.C. § 841 — Prohibited acts — manufacturing, distribution, dispensing (unlawful to manufacture, distribute, or dispense a controlled substance except as authorized; penalty schedules based on drug type and quantity)
• 21 U.S.C. § 844 — Penalties for simple possession (first offense: up to 1 year and/or $1,000 fine; enhanced penalties for subsequent offenses)

How It Works

The drug scheduling system is the backbone of federal drug policy under the Controlled Substances Act — determining which substances are controlled, how strictly they are regulated, and what penalties apply for violations. The five-schedule system balances public health, medical utility, and law enforcement in a framework that affects everything from your doctor's prescribing authority to federal prison sentences.

The five-schedule framework places substances based on two criteria: accepted medical use and abuse potential. Schedule I (heroin, LSD, MDMA, psilocybin, and — controversially — marijuana) has no currently accepted medical use, high abuse potential, and no accepted safety for supervised use; prescription is illegal and research barriers are the highest. Schedule II (fentanyl, oxycodone, morphine, methamphetamine, Adderall, cocaine used as a local anesthetic) has accepted medical use but high abuse potential; written prescriptions are required with no refills. Schedules III through V have progressively lower abuse potential and restriction — testosterone, ketamine, and some codeine combinations at III; benzodiazepines (Xanax, Valium) and sleep aids (Ambien) at IV; low-dose codeine cough preparations at V. Adding, removing, or changing a drug's schedule requires a formal regulatory process: DEA or HHS initiates proceedings, FDA conducts an eight-factor scientific evaluation, HHS makes a recommendation to DEA, and DEA publishes a proposed rule subject to public comment. The process typically takes years. In emergencies, DEA can temporarily schedule substances for 1–2 years while the full process proceeds — used extensively for fentanyl analogs and synthetic cannabinoids.

The most politically contentious scheduling issue is marijuana's Schedule I status. Despite 38+ states legalizing medical marijuana and 24+ legalizing recreational use as of 2026, marijuana remains federally classified alongside heroin as having "no currently accepted medical use." In 2022, President Biden directed HHS and DOJ to review marijuana's scheduling; HHS recommended rescheduling to Schedule III; as of 2026, DEA has proposed that rescheduling — which would recognize accepted medical use, ease research restrictions, and reduce federal criminal penalties, but would NOT legalize recreational marijuana at the federal level. The opioid epidemic has also tested the scheduling system from a different angle: Schedule II opioids caused millions of addictions despite legitimate prescriptions, prompting DEA to tighten manufacturing quotas, FDA to impose Risk Evaluation and Mitigation Strategies (REMS) on opioid prescribing, and Congress to expand access to addiction treatment medications. Illicit fentanyl and fentanyl analogs — often produced in China and Mexico and mixed into the drug supply — have become the leading cause of drug overdose deaths in the U.S., at approximately 75,000 per year.

How It Affects You

State Variations

Implementing Regulations

• 21 CFR Part 1308 — Schedules of Controlled Substances (the master DEA registry of every federally controlled substance, organized by schedule; 28 sections). Key provisions:

  • § 1308.03 — DEA Controlled Substances Code Number: every substance on a schedule is assigned a 4-digit DEA code number (e.g., heroin = 9200, cocaine = 9041, fentanyl = 9801); the code number appears on DEA order forms (DEA Form 222), import/export permits, and all official documentation — a single identifier that tracks the substance regardless of common name or brand
  • § 1308.11 — Schedule I listing: enumerates all Schedule I substances by chemical name and DEA code; the list is frequently amended — 90 FR 57356 and 90 FR 57542 (December 11, 2025) added several new synthetic opioids (nitazene analogs); 91 FR 13736 (March 23, 2026) made additional Schedule I additions; temporary scheduling orders (authorized by 21 U.S.C. § 811(h)) bypass the full rulemaking process to add new synthetic drugs for up to 3 years while permanent scheduling is considered
  • §§ 1308.12–1308.15 — Schedule II through V listings: each contains the substances by DEA code and chemical name; DEA may differentiate between isomers, salts, and analogs within the same code number, and may specify whether a listing covers only the dextro isomer (as with methamphetamine hydrochloride for Schedule II oral preparations) or all isomers
  • §§ 1308.21–1308.22 — OTC exclusions: any person may petition DEA to exclude a nonnarcotic drug from scheduling if it can be legally sold over the counter under the FDCA; DEA publishes a list of approved excluded substances (products with low concentrations of exempt narcotics or psychotropic substances); the exclusion only applies to the OTC product form — the pure substance remains scheduled
  • §§ 1308.23–1308.24 — Exempt chemical preparations: DEA may exempt specific low-concentration mixtures from some or all scheduling requirements; examples include codeine cough preparations with ≤200 mg per 100 ml qualifying as Schedule V rather than II (lower dispensing requirements) and combination products where the controlled substance is diluted to a level with low abuse potential; the exemptions are listed at § 1308.24
  • §§ 1308.25–1308.26 — Veterinary anabolic steroid exclusions: anabolic steroid products expressly intended for implants in cattle or other non-human species and approved by FDA are excluded from the Anabolic Steroid Control Act scheduling; the list of approved excluded products is at § 1308.26; producers of excluded vet products must still maintain records available to DEA

  Part 1308 is a living document — the Schedule I list is amended roughly 10–15 times per year as DEA uses its emergency temporary scheduling authority (21 U.S.C. § 811(h)) to quickly control newly identified synthetic drugs (fentanyl analogs, synthetic cannabinoids, novel benzodiazepines). The scheduling amendments appear in the Federal Register as either interim final rules (for temporary placements) or final rules (for permanent placements). The 2024 DEA proposal to move marijuana from Schedule I to Schedule III — if finalized — would require amending both §§ 1308.11 (removing it from Schedule I) and 1308.13 (adding it to Schedule III), triggering corresponding changes to prescribing rules (Part 1306), research registration requirements (Part 1301), and the tax treatment under IRC § 280E.

• 21 CFR Part 1301 — Registration of manufacturers, distributors, and dispensers (DEA registration requirements, application procedures, modification/transfer rules)

• 21 CFR Part 1306 — Prescriptions (prescription requirements for Schedule II-V substances, electronic prescribing, partial dispensing)

• 21 CFR Part 1312 — Importation and exportation of controlled substances (permits, declarations, advance notice requirements)

Pending Legislation

• HR 7970 — Permanently place nitazene opioids in Schedule I. Status: Introduced.
• S 3076 — Permanently put nitazenes in Schedule I, convert temporary listings. Status: Introduced.
• HR 8000 — Add synthetic 7-hydroxymitragynine to Schedule I, exclude natural kratom form. Status: Introduced.
• HR 6434 — Federal registration to let doctors give Schedule I drugs to Right to Try patients. Status: Introduced.
• S 3346 — Schedule I investigational drugs for Right to Try patients via DOJ registration. Status: Introduced.
• HR 4963 (Rep. Steube, R-FL) — Force AG to reclassify marijuana from Schedule I to III within 60 days. Status: Introduced.
• S 3048 — Let clinicians use telehealth for prescribing Schedule III-V drugs for substance use disorder. Status: Introduced.

Recent Developments

• Marijuana rescheduling stalls under Trump (2025): The Biden DEA proposed rescheduling cannabis from Schedule I to Schedule III in May 2024 — the most significant federal marijuana policy change in decades. The proposed rule went through a formal rulemaking period with extensive public comments. When the Trump administration took office, the fate of the rescheduling was uncertain — DEA under Trump could continue the rulemaking, modify it, or withdraw it. As of 2026, the process is continuing but on an uncertain timeline, with the cannabis industry watching closely. A Schedule III classification would significantly change federal tax treatment (currently dispensaries pay federal taxes under 280E at inflated effective rates) and could affect banking access, though it would not legalize marijuana.
• Fentanyl and novel synthetic opioids: Annual overdose deaths from synthetic opioids (primarily illicit fentanyl and fentanyl analogs) continue at approximately 75,000–80,000 per year — a national public health emergency. Emergency scheduling under the CSA has been used to place dozens of fentanyl analogs and new synthetic opioids into Schedule I rapidly. The Trump administration has prioritized fentanyl as a national security issue, linking it to border security and imposing tariffs on China and Mexico in part as leverage over fentanyl precursor chemicals.
• MDMA therapy not approved: The FDA rejected MDMA-assisted psychotherapy for PTSD treatment in August 2024, citing inadequate data and requesting a new Phase 3 trial. This set back the broader psychedelic medicine movement — including psilocybin-assisted therapy — which had hoped FDA approval of MDMA would open the door. Multiple states (Oregon, Colorado) have moved forward with state-level psilocybin frameworks regardless of federal scheduling status.
• DEA telehealth prescribing: The temporary pandemic-era rules allowing controlled substances to be prescribed via telehealth without an in-person evaluation are being phased out, with DEA finalizing new telehealth prescribing regulations for Schedule II-V controlled substances. This affects patients receiving ADHD medications, anxiety medications, and pain management through telehealth providers — requiring in-person evaluations to continue prescriptions in many cases.